We provide evidence that OTULIN is a crucial in vivo regulator of liver homoeostasis in mice and humans, identify mTOR signalling as a surprising driver of liver disease in OTULIN-deficient mice, and show that mTOR inhibition with rapamycin can improve liver pathology caused by OTULIN deficiency. The gene discussed is MTOR; the disease is liver disorder.